Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company dedicated to developing muscle activators and inhibitors aimed at addressing conditions where cardiac muscle performance is compromised. The company leads in muscle biology and mechanics, focusing on small molecule drug candidates specifically designed to enhance myocardial function and contractility. Cytokinetics is committed to a patient-centered approach, emphasizing integrity and scientific excellence in its operations. Collaboration across diverse teams and disciplines is key to their strategy, fostering innovation while ensuring that all actions and decisions support the needs of patients and caregivers. Their mission involves not only advancing treatments but also cultivating an inclusive workplace that values diverse experiences and perspectives.